Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation

Elisabeth Mémin¹, Mainul Hoque¹, Mohit R. Jain¹, Debra S. Heller², Hong Li¹, Bernadette Cracchiolo³, Hartmut M. Hanauske-Abel¹,³, Tsafi Pe'ery¹,⁴ and Michael B. Mathews¹

Departments of ¹Biochemistry & Molecular Biology, ²Pathology & Laboratory Medicine, ³Obstetrics, Gynecology & Women's Health, and ⁴Medicine, New Jersey Medical School, Rutgers University, Newark, NJ 07103

*Corresponding author. Address: Department of Biochemistry & Molecular Biology, New Jersey Medical School, Rutgers University, 185 South Orange Avenue, Newark, NJ 07103, USA. Phone: 973-972-4411. Fax: 973-972-5594. E-mail: mathews@njms.rutgers.edu

Key words: ciclopirox, deferiprone, translational control, eIF5A, hypusine, Hsp27, gene expression, RNA regulon

Running title
Drug targets & eIF5A hydroxylation in cervical cancer cells

Conflict of interest
The authors declare no conflicts of interest.
Abstract
Cancer etiology is influenced by alterations in protein synthesis which are not fully understood. In this study, we took a novel approach to investigate the role of the eukaryotic translation initiation factor eIF5A in human cervical cancers where it is widely overexpressed. eIF5A contains the distinctive amino acid hypusine, which is formed by a post-translational modification event requiring deoxyhypusine hydroxylase (DOHH), an enzyme that can be inhibited by the drugs ciclopirox and deferiprone. We found that proliferation of cervical cancer cells could be blocked by DOHH inhibition with either of these pharmacological agents, as well as by RNAi-mediated silencing of eIF5A, DOHH or other enzymes in the hypusine pathway. Proteomic and RNA analyses in HeLa cervical cancer cells identified two groups of proteins in addition to eIF5A that were coordinately affected by ciclopirox and deferiprone. Group 1 proteins (HSP27, NM23 and DJ-1) were downregulated at the translational level, whereas Group 2 proteins (TrpRS and PRDX2) were upregulated at the mRNA level. Further investigations of Hsp27 control confirmed that eIF5A and DOHH were required for its expression in cervical cancer cells and for regulation of its key targets IkB and NFκB there. Our results argue that mature eIF5A controls a translational network of cancer-driving genes, termed the eIF5A regulon, at the levels of mRNA abundance and translation. In coordinating cell proliferation, the eIF5A regulon can be modulated by drugs such as ciclopirox or deferiprone which might be repositioned to control cancer cell growth.

Precis: Findings suggest a mechanistic rationale to immediately reposition two approved drugs for cancer treatment, offering a low-risk clinical opportunity to evaluate new therapeutic modalities for cancer treatment.
Introduction

Despite advances in detection and prevention, cervical cancer remains the third most frequently diagnosed female cancer worldwide, with an estimated 275,000 deaths in 2008 (1). For the United States, the National Cancer Institute estimated that over 12,000 new cases will be diagnosed in 2013, and that every third patient with this diagnosis will die despite state-of-the-art treatment. The identification of novel targets in cancer cells and the analysis of the molecular response to their suppression will promote the rational development of novel therapeutic modalities.

Translation, a key process in the gene expression pathway, is often dysregulated in cancer (2). A strong correlation has been established between cancer and over-expression of the eukaryotic initiation factor 5A (eIF5A), which functions in protein synthesis (3). Humans have two eIF5A isoforms: eIF5A1, expressed in many normal tissues, and eIF5A2, which enjoys more limited expression and distribution. Elevated levels of both isoforms characterize a variety of cancers and tumor-derived cell lines, and accumulating evidence links eIF5A to cell proliferation, cancer progression, invasiveness, metastasis and poor clinical prognosis (3, 4).

Both isoforms carry the amino acid hypusine, which is apparently unique to eIF5A and essential for many (if not all) of its functions (3). Hypusine is formed post-translationally in sequential reactions catalyzed by two dedicated enzymes, deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) (Fig. 1A). The singularity of this pathway presents attractive targets for drug development and cancer therapy (5).

The involvement of DOHH in cell cycle progression was recognized early (6), and specific inhibitors were characterized (7). Of particular interest are two drugs that inhibit DOHH and hypusine formation at clinically relevant concentrations: ciclopirox (CPX), a topical antifungal (8), and deferiprone (DEF), used to treat transfusional iron-overload such as in thalassemia (9). Both drugs block cell proliferation and display anti-neoplastic potential. Thus CPX has been shown to inhibit the proliferation of cells in culture (10-12) and of breast cancer and myeloma xenograft growth in mice (11-13). CPX also inhibits angiogenesis and lymphangiogenesis in established culture models (10, 14). DEF inhibits the growth of HeLa cells derived from cervical carcinoma as well as other
cancer cell lines (15), and its analog mimosine slows the growth of subcutaneous lung and pancreatic cancer xenografts in mice (16). The DHS substrate analog GC7 (Fig. 1A) also impairs cancer cell growth, for example of glioblastoma cells (17).

This study addresses the relationship between eIF5A, hypusine and gene expression in cervical cancer, and identifies cellular protein targets of the drugs CPX and DEF. We show that mature, hypusyl-eIF5A1 is highly expressed in proliferating cervical cancer tissue, of both the squamous cell and adenocarcinoma types, and in adenocarcinoma-derived HeLa cells. Cell proliferation was inhibited, and morphological changes occurred, after treatment with the drugs or eIF5A silencing. We devised a proteomic approach (Fig. 1B) to identify proteins that are regulated by both CPX and DEF using HeLa cells as a model. Five proteins, in addition to mature eIF5A itself, were identified whose synthesis and accumulation were coordinately affected by these drugs. The proteins play key roles in cancer cell proliferation, survival and metastasis, and fall into two groups. Group 1 proteins were down-regulated by the drugs at the translational level, whereas Group 2 proteins were up-regulated at the mRNA level. The Group 1 protein Hsp27, a molecular chaperone, is a cancer biomarker and potential target for cancer therapy (18). RNA interference experiments demonstrated that hypusyl-eIF5A is required for Hsp27 synthesis and modulates transcription via nuclear factor κB (NFκB).

Our data suggest that mature eIF5A1 regulates the expression of a set of genes, designated the eIF5A regulon, that are required for cell proliferation. Taken together, these findings prompt the design of clinical trials to examine the utility of the drugs CPX and DEF, and related agents, in anti-cancer therapy.

**Materials and Methods**

**Immunohistochemistry**

Cervical cancers were diagnosed by an experienced pathologist as squamous cell carcinoma (12 samples) or adenocarcinoma (9 samples). Tissue sections were stained for eIF5A using NIH-353 antibody (kindly provided by Dr. M.H. Park) and with Ki-67 antibody (Dako, Glostrup, Denmark) as described previously, in compliance with an
IRB-approved protocol allowing anonymous use of archival, formalin-fixed, paraffin-embedded biopsy material (5).

**Cell culture**
Cells from the American Type Culture Collection were maintained as recommended and seeded one day before treatment. CPX (Sigma-Aldrich, St. Louis, MO, USA) and DEF (Calbiochem, San Diego, CA, USA) were freshly dissolved in PBS and added to the medium for 24 to 72 hr.

**Immunoblotting**
Cells were lysed as described previously (19). Proteins were assayed (Bio-Rad DC protein assay, BioRad, Hercules, CA, USA) and 1 to 20 μg samples were resolved in SDS-polyacrylamide gels. After transfer to PVDF membranes, blots were probed with primary antibody followed by horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA). Rabbit anti-peroxiredoxin 2 antibody was from Upstate Cell Signaling (Lake Placid, NY, USA), mouse anti-eIF5A and anti-NM23 from Becton Dickinson (BD; Transduction Laboratories, San Jose, CA, USA), mouse anti-TrpRS and anti-Hsp27 from Novus Biologicals (Littleton, CO, USA), rabbit anti-DJ-1 from Cell Signaling Technology (Danvers, MA, USA), and mouse anti-β-actin and anti-α-tubulin from Sigma (St. Louis, MO). Rabbit anti-DOHH antibody was kindly provided by Dr. Myung Hee Park (NIH/NIDCR, Bethesda, MD). Signal was detected using enhanced chemiluminescence.

**RNA interference**
For cell growth assays, HeLa cells were transfected with 20 nM siRNA and U2OS cells with 50 nM siRNA using Hiperfect (Qiagen, Valencia, CA, USA). Cells were harvested at 72 hr post-transfection unless otherwise stated. siRNA sequences (sense/antisense) were as follows: eIF5A1 (Ambion, Austin, TX, USA), 5'-GGUCCAUCCUGGUUGGUAUUTT/5'-AAUACCAACCAGAUGGACCTT; luciferase (Ambion) as negative control for HeLa cell proliferation assays, 5'-CGUACGCGGAAUACUUCGATT/5'-UCGAAGUAUUCGCCGUACGTT. DHS and
DOHH “ON-TARGET plus SMART pool” and non-targeting control siRNAs were from Dharmacon (Lafayette, CO). For luciferase assays, HeLa cells were transfected with 50nM siRNA using Hiperfect (Qiagen, Valencia, CA, USA). Cells were re-seeded at 48 hr and co-transfected at 72 hr with the HIV-1 molecular clone pNL4-3 lucE− and pCMV-Renilla plasmid using Jet-PEI (polyplus transfections). Cells were harvested 24 hrs later and expression of reporter genes analyzed (19).

**Metabolic labeling**

HeLa cells were incubated for 21 hr with 30 μM CPX or 200 μM DEF, washed twice with PBS and once with DMEM lacking methionine and cysteine, then incubated for 3 hr in the same medium containing 50 μCi/ml of Trans[35S]-label (MP Biomed, Solon, OH) with drug as appropriate. Cells were washed with ice-cold PBS before scraping. For measurement of hypusine and deoxyhypusine synthesis, cells were labeled with [3H]-spermidine for 24 hr and analyzed as described previously (20).

**Two-dimensional (2D) gel electrophoresis and protein identification**

HeLa cell extracts were prepared by incubation for 30 min at 4°C in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM dithiothreitol, 0.1% SDS, 50 mM NaF, 1 mM Na orthovanadate, and protease inhibitor cocktail from Sigma-Aldrich), and analyzed in 2D gels (21). Non-radioactive gels were fixed (40% ethanol, 10% acetic acid), stained with SYPRO® Ruby (BioRad), and scanned on a Typhoon scanner (GE Healthcare, Piscataway, NJ, USA). Radioactive gels were dried under vacuum and exposed to autoradiography film. Spot intensities were compared visually in 3 replicate experiments for each of the analysis using spots with unchanged densities as landmarks. Spots from stained gels were processed for MALDI-TOF-TOF MS analysis ((21); Supplementary Table S1).

**RNA extraction and real-time PCR (RT-PCR)**

Total RNA was isolated using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA). cDNA was generated using 2 μg total RNA, random hexamers and MultiScribe reverse transcriptase (Applied Biosystems, Foster City, CA). PCR was performed in an Applied
Biosystems 7500 apparatus, using SYBR green mix (Roche Applied Biosystems, Foster City, CA) and AmpErase (Applied Biosystems). Primers were: Hsp27, 5'-GACACTCCTGAGCCAGAGCAG/5'-GTCAACTCTTTTGGTGGACG; NM23, 5'-CCATTCTTGGCCGCTG/5'-GTGAAAAGCAATGTTGCTTG; PRDX2, 5'-GGCGCATCGGAAACAGC/5'-CAAGCGTCTGGTCACGT; TrpRS, 5'-GGAGCTGTCAACACCGCTG/5'-CTTCTACAGCAGCATAGCT; eIF5A1, 5'-GACTTCCAGCTGATTGTGGCATCCAG/5'-GCAGGCCTTATTGTCCTGCACTTG; DJ-1, 5'-GTGTCATGAGGCGAGGCTGG/5'-CTCCTACAGCAGCATAGCT; β-actin, 5'-AAATCGTGACATTAAGG/5'-AGCAGTGTGGTGCCATACG.

**Results**

**eIF5A expression in human cervical carcinoma**

eIF5A is over-expressed in a number of malignant tissues including vulvar high-grade intraepithelial neoplasia (VIN), the precursor to vulvar cancer (5). To evaluate expression in cervical cancer we conducted immunohistochemical studies with NIH-353 antibody, which recognizes mature hypusyl-eIF5A1 (5), and with Ki-67 antibody to identify proliferating cells. NIH-353 immunoreactivity located strictly to Ki-67–positive areas in both major types of cervical cancer, i.e. invasive solid tumor cords and nests in squamous cell carcinoma and invasive vacuole-containing glandular sheets of columnar cells in adenocarcinoma (Fig. 2A). These observations indicate that hypusyl-eIF5A1 is highly expressed in the vast majority of cervical tumors.

Correspondingly, hypusyl-eIF5A is abundant in HeLa cells, derived from cervical adenocarcinoma. Immunoblotting with NIH-353 antibody revealed varying levels of expression among cancer cell types (Fig. 2B). Comparison with U2OS cells (derived from osteosarcoma) indicates a range of at least 5-fold in proliferating cell lines (Fig. 2C). The high level of mature eIF5A1 observed in HeLa cells corroborates previous observations (20), matching its high expression in cervical cancer biopsies (Fig. 2A).
Mature eIF5A is required for cell growth

RNA silencing was deployed to determine whether eIF5A1 over-expression is directly involved in cell proliferation. Reduction in HeLa cell number became evident 4 days after transfection with siRNA directed against eIF5A1 (si5A) compared to control siRNA (siC) (Fig. 3A, top). Inhibition of cell proliferation correlated with the reduction in the eIF5A1 protein level (Fig. 3A, bottom). Notably, both declined more rapidly in U2OS cells which contain less eIF5A (Fig. 3B). Furthermore, depletion of the eIF5A modifying enzyme DOHH (Fig. 1A) also reduced proliferation of HeLa and U2OS cells (Fig. 3A,B). These data indicate that hypusyl-eIF5A is critical for cell proliferation in both of these cancer cell lines.

CPX and DEF inhibit eIF5A maturation and cell proliferation

We used HeLa cells to study the effects of two drugs, CPX and DEF, which inhibit the hydroxylation of deoxyhypusyl-eIF5A by DOHH (Fig. 1A). To monitor the drugs' action in HeLa cells, we measured hypusine formation by labeling eIF5A with [3H]-spermidine. Inhibitor constants, Ki, were 6.25 μM for CPX and 152 μM for DEF (Supplementary Fig. S1). Pharmacological concentrations of CPX (30 μM) or DEF (200 μM) (10, 19), suppressed hypusine labeling by >90% with concomitant appearance of deoxyhypusine (Fig. 3C). Immature forms of eIF5A1 accumulated in the presence of the drugs as revealed by 2D-gel electrophoresis (Fig. 3D). Without drug treatment, eIF5A was represented by a single predominant spot with a pI of ~5.3, corresponding to hypusyl-eIF5A (22). Treatment with CPX or DEF led to the appearance of two spots with more acidic pI's (~5.2 and ~5.1) associated with acetylated forms of deoxyhypusyl-eIF5A (23). Thus the drugs prevented the maturation of eIF5A and led to the accumulation of its immediate precursor, deoxyhypusyl-eIF5A.

Consistent with their inhibitory action on DOHH, both drugs rapidly inhibited HeLa cell proliferation (Fig. 3E), similar to the effects of eIF5A or DOHH knockdown (Fig. 3A). Drug-treated cells retained >93% of control viability at 24 hr, exhibited minimal apoptosis, and were arrested in the G1/S phase of the cell cycle (Supplementary Fig. S2), as reported previously, (6, 7, 15)(26). They exhibited morphological changes and
an increase in size (Supplementary Fig. S3), reminiscent of the phenotype of eIF5A-deficient yeast (24, 25).

Modulation of protein expression by CPX and DEF

eIF5A is believed to be required for the translation of a specific class of proteins (24, 26). Since CPX and DEF inhibit eIF5A maturation and HeLa cell proliferation, we sought to identify cellular proteins that are downstream targets of the drugs. Our strategy combined the analysis of protein levels and translation in drug-treated and untreated cells using 2D gels (Fig. 1B). Representative gel images are presented (Supplementary Fig. S4), together with sections of stained gels (Fig. 4A) and [35S]-labeled gels (Fig. 4B) containing spots whose intensities changed with drug treatment. Several spots decreased in intensity as expected (e.g., spot 10), but others were observed to increase (e.g., spot 6).

We enumerated the spots in both the staining and labeling analyses that increased, decreased, or were unaltered in intensity after drug treatment (Fig. 4C). The overwhelming preponderance of spots did not change in intensity with CPX or DEF. Among those that did change, attention was focused on proteins whose labeling and accumulation varied in parallel (Criterion 1, Fig. 1B). With CPX, five spots decreased and three spots increased in both types of analysis; with DEF, eight spots decreased and five increased in both types of analysis (highlighted in Fig. 4C).

Since the drugs might impinge on cellular pathways in addition to that involving eIF5A, we further limited consideration to spots that were affected in the same way by CPX and DEF (Criterion 2). Seven spots varied coordinately with the two drugs: three increased and four decreased. It is notable that all three proteins up-regulated by CPX and nearly all (4/5) of the down-regulated proteins were shared with DEF, and that most (3/5) of the proteins up-regulated by DEF and half (4/8) of the down-regulated proteins were in common. This high degree of concordance lends confidence that the changes reflect a common pharmacological target and biochemical pathway.

Identification of DOHH-dependent proteins
Proteins whose synthesis was affected by both drugs were eluted from unlabelled gels, analyzed by MS, and identified through database searches (Fig. 5A; Supplementary Table S1). Identifications were checked by immunoblotting with specific antibodies (Criterion 3, Fig. 1B). All were confirmed except for one up-regulated protein identified as 4-hydroxyphenylpyruvate dioxygenase (4-HPD), which could not be detected by immunoblotting (data not shown). Accordingly, 4-HPD is not included in the list of identified proteins and was not pursued further.

In addition to eIF5A1, the down-regulated proteins are heat shock protein 27 (Hsp27), DJ-1 (PARK7), and non-metastatic protein 23 (NM23), designated Group 1. The confirmed up-regulated proteins, designated Group 2, are peroxiredoxin 2 (PRDX2) and tryptophanyl-tRNA synthetase (TrpRS).

**Differential regulation of gene expression by the drugs**

Immunoblotting and real-time (RT)-PCR were conducted to examine the effect of CPX and DEF on the identified proteins and their cognate mRNAs (Fig. 5B-G).

Consistent with the action of the drugs on its post-translational modification (Fig. 3C,D), eIF5A1 expression was not significantly affected at the total protein level (Fig. 5B, filled bars) or at the RNA level (Fig. 5B, gray bars).

On the other hand, CPX and DEF reduced the expression of Hsp27, NM23 and DJ-1 proteins (Fig. 5C-E, filled bars), in agreement with the 2D-gel data. The degree of inhibition was ~50% with CPX and ~30% with DEF. Exceptionally, the DEF-induced reduction in the level of DJ-1 was less, possibly because the drug affects the oxidation status of this protein resulting in a change that is registered primarily in 2D gels (27). As with eIF5A1, RT-PCR revealed no significant changes in transcript levels (Fig. 5C-E, gray bars), indicating that the down-regulation of Group 1 proteins by the drugs is due to translational control.

The drug-induced up-regulation of PRDX2 and TrpRS was confirmed by immunoblotting (Fig. 5F,G, filled bars). Increased expression of these proteins was accompanied by increased levels of their transcripts (Fig. 5F,G gray bars), indicating that CPX and DEF up-regulate Group 2 proteins at the level of mRNA transcription or
stability. Interestingly, the increase in TrpRS RNA markedly exceeded that of the protein, possibly reflecting its secretion as an angiostatic factor (discussed below).

**Mature eIF5A modulates Hsp27 levels and NFκB activity**

To document the connection between a drug target and eIF5A modification, we selected Hsp27 for further study. Hsp27 expression is increased in high-grade intraepithelial neoplasia and squamous cell carcinoma of the cervix (28) and several other cancers. It has been directly implicated in tumor progression (29) and radio- and chemoresistance (18). Furthermore, Hsp27 activates signaling via the transcription factor NFκB by facilitating the turnover of its inhibitor IκB (30).

Our findings with CPX and DEF (Fig. 5C) suggested that hypusyl-eIF5A is required for elevated Hsp27 synthesis and, by extension, for NFκB-dependent transcription. To examine these inferences we depleted HeLa cells for eIF5A1 or its modifying enzymes. Immunoblotting showed that siRNA directed against eIF5A1, DHS or DOHH reduced the level of Hsp27 (Fig. 6A), as with drug treatment (Fig. 5C), and led to concomitant elevation of IκB as predicted (Fig. 6A).

NFκB is essential for HIV-1 transcription (31), and CPX and DEF have been shown to inhibit expression from the HIV-1 promoter (19). We therefore depleted HeLa cells for eIF5A1, DHS or DOHH, then transfected with an HIV-1 molecular clone expressing firefly luciferase. Reporter gene expression was inhibited by 50-60% in all cases (Fig. 6B). Since IκB is barely detectable in control cells (Fig. 6A), these results indicate that hypusyl-eIF5A plays an important role in regulating Hsp27 levels and NFκB activity in HeLa cells.

**Discussion**

The identification of two groups of target proteins sensitive to CPX and DEF has implications for the regulation of gene expression by eIF5A and for the exploration of the drugs’ therapeutic potential in cancer.

**Robustness of target identification**
The cornerstone of our strategy for identifying drug targets was multiplexed 2D-gel analysis, and its reliability follows from the stipulation of three stringent criteria (Fig. 1B). First, we considered only those proteins that responded in the same way to drug treatment when staining and labeling analyses were compared. Of the spots that increased or decreased in at least one type of analysis, ~25% (21/82) satisfied this criterion (Fig. 4C). Second, we demanded coordinate response to CPX and DEF: seven of the remaining spots satisfied this criterion. Third, after identification by MS, we required confirmation by immunoblotting: six proteins met this final criterion (Fig. 5A), testifying to the rigor of the overall strategy.

Criterion 1 was evidently an effective filter, but the requirement for consistent behavior probably eliminated genuine drug targets that turn over slowly. Indeed, almost half of the spots with altered intensity (30/61) displayed decreased labeling but unchanged staining, hallmarks of proteins with long half-lives. Most of the other discordant spots were unchanged in labeling yet increased (15/61) or decreased (10/61) in staining, perhaps signifying post-translational processing. A few (5/61) increased in labeling without a change in staining, possibly attributable to a large protein pool size. Reassuringly, only one spot behaved anomalously, increasing in one type of analysis and decreasing in the other.

Criterion 2, which was motivated by the likelihood that drugs can have differential side-effects, was also an effective filter. It eliminated seven spots that displayed drug-specific behavior, potential false positives that were more prevalent with DEF (6 spots) than CPX (1 spot).

Although robust, it should also be noted that the protocol favors proteins that are relatively abundant, rapidly synthesized, and methionine/cysteine-containing. Some 300 proteins were surveyed in our gels, a sampling of <1% of the human proteome, so the target proteins identified almost certainly represent a subset of those affected by CPX and DEF.

**Putative eIF5A regulon**

Results presented here (Fig. 3C,D) establish that CPX and DEF inhibit DOHH in HeLa cells, leading to a deficit in hypusine and accumulation of deoxyhypusine in
eIF5A. Although both drugs chelate iron (8, 9) the lowering of intracellular iron is insufficient for this activity (19)(Hanauske-Abel et al., PLOS ONE in press). Rather, they appear to fit into the enzyme’s active site and abstract its iron, causing structural collapse (19). While contributions of other pathways cannot be ruled out, the evidence points to eIF5A maturation as the primary target with far-reaching consequences including inhibition of cell proliferation resulting from the depletion of hypusyl-eIF5A and/or the accumulation of deoxyhypusyl-eIF5A (Fig. 3).

The five newly-identified drug-sensitive proteins (Fig. 5A) are not documented cellular binding partners of eIF5A or its modifying enzymes (32), nor do they uniformly harbor proline-rich translational signals characterized for the bacterial eIF5A homolog EF-P (Supplementary Figure S5). Rather, they appear to be secondary drug targets regulated by hypusyl-eIF5A, as demonstrated for Hsp27 (Fig. 6), and they fall into two groups distinguished by both the direction of the drug response and the level at which it is exerted.

- **Group 1** targets are down-regulated by CPX and DEF apparently at the level of translation, consistent with the function of eIF5A in protein synthesis (33). Depletion of eIF5A in yeast decreases protein synthesis only partially (24, 34), however, implying that it functions as a selective translational enhancer for Group 1 mRNAs.

- **Group 2** targets are up-regulated at the RNA level by CPX and DEF, indicating that their transcription or mRNA stability is increased. eIF5A has been implicated in mRNA turnover in yeast (34) and human cells (Hoque et al., unpublished results), suggesting that eIF5A-dependent selective turnover could be responsible for Group 2 mRNA regulation.

Coordinate regulation of these proteins has also been observed in proteomic studies of cells treated with other agents. For example, the expression of eIF5A and NM23 is induced, and that of PRDX2 and TrpRS is repressed, after p53 activation by mitomycin C (35). We therefore advance a model (Fig. 7) in which hypusyl-eIF5A1 modulates a regulon, or RNA operon (36), that controls cell proliferation and possibly other processes such as the response to oxidative stress. Mechanistically, we envision that eIF5A (or possibly one or more of its target proteins) preferentially binds a subset of cellular mRNAs (37) and recruits additional mRNA-binding proteins that impinge
differentially on the two groups of gene products, thereby facilitating the translation of Group 1 mRNAs and accelerating the turnover of Group 2 mRNAs.

**Oncological implications**

Like eIF5A, Group 1 proteins are associated with cell proliferation and cancer (38-40). The best characterized is the chaperonin Hsp27, a marker for unfavorable prognosis in many human cancers and a potential therapeutic target (18, 29, 41, 42). Similarly, DJ-1 is highly expressed in a number of human cancers (40). DJ-1 enhances cell survival via activation of NFκB and its silencing inhibits cell proliferation (40, 43). NM23 catalyzes the phosphorylation of nucleoside diphosphates and its expression is related to cell proliferative activity (44). Although initially considered an inhibitor of metastasis, accumulating data reveal differential expression of NM23 isoforms and indicate a more complex relationship with cancer. Recent work identified NM23 as a predictor of poor survival in pancreatic cancer (45). Furthermore, all three Group 1 proteins associate with factors that control cell shape, providing a plausible explanation for the morphological changes brought about by CPX and DEF which are possibly related to cell motility changes and metastasis (40)(Supplementary Fig. S4). Thus, the down-regulation of Hsp27, DJ-1 and NM23 by CPX and DEF suggests that these drugs could have a therapeutic effect in malignancies characterized by over-expression of Group 1 proteins.

Conversely, Group 2 proteins can exert negative effects on cell proliferation. High TrpRS expression correlates with lower risk of recurrence and increased survival in patients with colorectal cancer (46). In addition to its canonical intracellular role in tRNA aminoacylation, N-terminally truncated forms of TrpRS are secreted and have anti-angiogenic activity, blocking vascular endothelial growth factor-induced cell proliferation and migration (47, 48). Thus, like interferon-γ administration, drug-induced increase of TrpRS is consistent with anti-angiogenic and anti-proliferative activity that could discourage tumor growth. PRDX2 is a member of a family of cellular peroxidases that have a complex relationship with tumor formation (49). The growth of breast cancer cells that metastasize to lung was inhibited by PRDX2 knockdown whereas over-expression in bone metastatic breast cancer cells reduced the skeletal tumor burden.
and bone destruction (50). This suggests that the enzyme prevents tumor growth in hypoxic conditions, possibly signaled by deoxyhypusyl-eIF5A, although it protects against oxidative stress in oxygen-rich environments. Therefore up-regulation of Group 2 proteins by CPX and DEF may restrain the growth of certain tumors.

In summary, we propose that eIF5A coordinates a set of genes at the level of translation (increased) and of mRNA abundance (decreased, possibly by facilitating mRNA decay). These genes define an eIF5A regulon that activates cell proliferation, and loss of eIF5A function has anti-cancer effects. The widely-used drugs CPX and DEF interfere with eIF5A post-translational modification and function, therefore qualify as candidates for exploratory oncological trials and further drug development. Consistent with this conclusion, oral CPX has shown promise in treating patients with acute myelogenous leukemia in a recent proof-of-concept trial (AD Schimmer, personal communication).

Acknowledgments
We thank Anita Antes for invaluable assistance, Dr. Jyoti Mundra for contributions to RNAi experiments, and the Foundation of UMDNJ for support. Apologies for limited literature citation.

References


**Legends**

**Fig. 1. Pathway of eIF5A modification and experimental strategy.**

**A:** Hypusine formation and inhibition. DHS catalyzes aminobutyl (blue) transfer from spermidine onto the ε-amino group of lysine-50 of human eIF5A (gray) using NAD⁺ as cofactor, yielding deoxyhypusine (Dhp). DOHH hydroxylates Dhp to hypusine (Hpu) in an Fe(II)-dependent reaction using molecular oxygen. The spermidine analog GC7 (N1-guanyl-1,7-diaminoheptane) inhibits DHS. The drugs ciclopirox (CPX; 6-cyclohexyl-1-hydroxy-4-methyl-(1H)-pyrid-2-one) and deferiprone (DEF; 1,2-dimethyl-3-hydroxypyridin-4-one) inhibit DOHH. (From (19).)

**B:** Strategy for identification of CPX- and DEF-dependent proteins.
Fig. 2. eIF5A expression in cervical cancer and in cancer-derived cell lines.

A: Tissue localization of mature, hypusyl-eIF5A1 (detected by NIH-353; left) and of Ki-67 protein (right) by immunohistochemical staining of squamous cell carcinoma (top; neighboring sections) and adenocarcinoma (bottom; adjacent sections). Bars: 600 μm. NIH-353 strongly stains infiltrating malignant areas and faintly stains glandular structures (arrow) and non-malignant tissue elements, reproducing the Ki-67 pattern. B: Expression of eIF5A in cell lines. Whole cell extracts (10 μg protein) were analyzed by immunoblotting using antibody NIH-353 against eIF5A with actin as standard. C: As B, comparing the indicated amounts of HeLa and U2OS protein, standardized with tubulin against eIF5A. C: As B, comparing the indicated amounts of HeLa and U2OS protein, standardized with tubulin.

Fig. 3. Hypusyl-eIF5A requirement for cell proliferation.

A: HeLa cells were transfected with siRNA directed against eIF5A or DOHH, or with control siRNA (siC). Trypan blue-excluding viable cells were counted (top) and cell extract protein (1 μg) was analyzed by immunoblotting (bottom) on the days indicated. eIF5A was detected by eIF5A1 (BD) antibody directed against the protein’s C terminus (independent of hypusine modification). B: As A, using 10 μg samples of U2OS cell extract protein. C: HeLa cells were incubated with [3H]-spermidine and CPX (30 μM) or DEF (200 μM) as indicated. Acid hydrolysates were fractionated and fractions assayed for radioactivity. Positions of [3H]-hypusine and [3H]-deoxyhypusine are indicated. D: Extracts of cells treated with CPX or DEF were resolved in 2D gels. eIF5A was detected using BD antibody (arrows: spots with similar pI). E: Cell proliferation in HeLa cell cultures exposed to the drugs.

Fig. 4. Effects of CPX and DEF on HeLa cell protein synthesis and accumulation.

A: Extracts of HeLa cells treated with CPX or DEF and control cells were resolved in 2D gels and stained with SYPRO® Ruby. Sections show representative differentially-expressed stained spots (arrows). B: As A, except that the cells were labeled with [35S]-methionine and -cysteine and spots were detected by autoradiography. C: Enumeration of 2D-gel spots that changed after treatment with CPX (left numbers) or DEF (right
numbers) as detected by staining (columns) and labeling (rows). Bold-bordered numerals denote concordant spots, which were examined further. Italicized numerals denote discordant spots.

Fig. 5. Identification and expression of drug-regulated proteins.
A: Identity and properties of proteins affected by both CPX and DEF and identified by MS. Molecular weights (MW) and isoelectric points (pI) were calculated from protein sequences (www.phosphositeplus.org and www.expasy.org). B-G: Gene expression analysis of drug effects in HeLa cells. Top: Immunoblot analysis of the down-regulated (B-E) and up-regulated (F,G) proteins with actin as a control. Bar graphs: Protein levels relative to actin were evaluated by immunoblotting (filled bars) and corresponding RNA levels were assayed using real-time PCR (grey bars). Data are means of 3 independent experiments with SD.

Fig. 6. Depletion of mature eIF5A induces IkB and inhibits transcription directed by the HIV-1 promoter.
HeLa cells were transfected with siRNAs directed against eIF5A, DHS or DOHH or control siRNA, then with pCMV-Renilla and the HIV-1 molecular clone pNL4-3lucE- encoding firefly luciferase (FF). A: Immunoblot analysis. eIF5A was detected with BD antibody. B: Expression of FF luciferase normalized to Renilla luciferase activity with SD.

Fig. 7. Model for the function of the eIF5A regulon.
Mature eIF5A is proposed to affect protein expression differentially by enhancing the translation of Group 1 mRNAs, but the turnover of Group 2 mRNAs (see text for details).
Fig. 1. Mémin et al.

A

Hypusine synthesis pathway

\[ \text{eIF5A-Lys} \rightarrow \text{NH}_2 \rightarrow \text{NH} \rightarrow \text{DHS} \rightarrow \text{GC7} \rightarrow \text{CPX, DEF} \rightarrow \text{eIF5A-(Dhp)} \rightarrow \text{eIF5A-(Hpu)} \]

B

Identification of CPX- and DEF-dependent proteins

HeLa cells incubated for 24 hr with CPX, DEF, or no drug (control)

\[ 2\text{D gels} \rightarrow ^{35}\text{S label for the last 3 hr} \rightarrow 2\text{D gels} \rightarrow \text{staining} \rightarrow \text{autoradiography} \]

Criteria 1 & 2

spots with consistently altered intensity

criteria 3

protein identification by MS/MS

immunoblot analysis of protein expression changes

RNA analysis of selected genes by RT-PCR
Fig. 2. Mémin et al.

A

B

C

<table>
<thead>
<tr>
<th></th>
<th>AS46</th>
<th>BEX4-28</th>
<th>Hep G2</th>
<th>Hela</th>
<th>Hela</th>
<th>Hela</th>
<th>HT29</th>
<th>Hela</th>
<th>MDA-MB-231</th>
<th>PC3</th>
<th>SA-879Y</th>
<th>U2OS</th>
<th>UACC</th>
<th>U-251</th>
<th>U-373</th>
</tr>
</thead>
<tbody>
<tr>
<td>elf5A</td>
<td>3</td>
<td>1</td>
<td>0.3</td>
<td>0.1</td>
<td>3</td>
<td>1</td>
<td>0.3</td>
<td>0.1</td>
<td>3</td>
<td>1</td>
<td>0.3</td>
<td>0.1</td>
<td>3</td>
<td>1</td>
<td>0.3</td>
</tr>
</tbody>
</table>

HeLa

U2OS

elF5A

actin

tubulin
Fig. 3. Mémin et al.

(A) HeLa cells

(B) U2OS cells

(C) Hypusine and deoxyhypusine profiles

(D) Western blots

(E) Cell number over time
**Fig. 4. Mémin et al.**

<table>
<thead>
<tr>
<th>Spot number</th>
<th>Control</th>
<th>CPX</th>
<th>DEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td><img src="image1.png" alt="Image of stained proteins" /></td>
<td><img src="image2.png" alt="Image of stained proteins" /></td>
<td><img src="image3.png" alt="Image of stained proteins" /></td>
</tr>
<tr>
<td>10</td>
<td><img src="image4.png" alt="Image of stained proteins" /></td>
<td><img src="image5.png" alt="Image of stained proteins" /></td>
<td><img src="image6.png" alt="Image of stained proteins" /></td>
</tr>
</tbody>
</table>

**Stained proteins**

<table>
<thead>
<tr>
<th>Spot number</th>
<th>Control</th>
<th>CPX</th>
<th>DEF</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td><img src="image7.png" alt="Image of labeled proteins" /></td>
<td><img src="image8.png" alt="Image of labeled proteins" /></td>
<td><img src="image9.png" alt="Image of labeled proteins" /></td>
</tr>
<tr>
<td>10</td>
<td><img src="image10.png" alt="Image of labeled proteins" /></td>
<td><img src="image11.png" alt="Image of labeled proteins" /></td>
<td><img src="image12.png" alt="Image of labeled proteins" /></td>
</tr>
</tbody>
</table>

**Labeled proteins**

### Table C

<table>
<thead>
<tr>
<th>Number of stained spots</th>
<th>Unchanged</th>
<th>Increased</th>
<th>Decreased</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPX ▶ DEF</td>
<td><img src="image13.png" alt="Image of table" /></td>
<td><img src="image14.png" alt="Image of table" /></td>
<td><img src="image15.png" alt="Image of table" /></td>
</tr>
<tr>
<td>Unchanged</td>
<td>~300 ▶ ~300</td>
<td>11 ▶ 4</td>
<td>9 ▶ 1</td>
</tr>
<tr>
<td>Increased</td>
<td>4 ▶ 1</td>
<td>3 ▶ 5</td>
<td>0 ▶ 0</td>
</tr>
<tr>
<td>Decreased</td>
<td>24 ▶ 6</td>
<td>1 ▶ 0</td>
<td>5 ▶ 8</td>
</tr>
</tbody>
</table>
### Table: Protein Summary

<table>
<thead>
<tr>
<th>Group</th>
<th>Protein</th>
<th>NCBI Protein Accession No. (gi)</th>
<th>pI</th>
<th>MW (Da)</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>eIF5A</strong>: eukaryotic initiation factor 5A</td>
<td>4503545</td>
<td>5.07</td>
<td>16,832</td>
<td><strong>Protein synthesis</strong></td>
</tr>
<tr>
<td>1</td>
<td><strong>Hsp27</strong>: heat shock protein 27</td>
<td>4504517</td>
<td>5.98</td>
<td>22,783</td>
<td><strong>Chaperone</strong></td>
</tr>
<tr>
<td>1</td>
<td><strong>NM23</strong>: non-metastatic protein 23</td>
<td>17512044</td>
<td>5.81</td>
<td>17,149</td>
<td><strong>Nucleoside diphosphate kinase</strong></td>
</tr>
<tr>
<td>1</td>
<td><strong>DJ-1</strong>: parkinson disease 7</td>
<td>50513593</td>
<td>6.33</td>
<td>19,891</td>
<td><strong>Sensor of oxidative stress. Transcriptional activator.</strong></td>
</tr>
<tr>
<td>2</td>
<td><strong>PRDX2</strong>: peroxiredoxin-2 isoform a</td>
<td>32189392</td>
<td>5.66</td>
<td>21,892</td>
<td><strong>Redox regulation Antioxidant</strong></td>
</tr>
<tr>
<td>2</td>
<td><strong>TrpRS</strong>: tryptophanyl-tRNA synthetase</td>
<td>340368</td>
<td>5.8</td>
<td>53,165</td>
<td><strong>Protein synthesis Angiogenesis inhibitor</strong></td>
</tr>
</tbody>
</table>

### Figures:

#### Figure B
- **eIF5A**: actin expression.
- **Hsp-27**: actin expression.
- **NM23**: actin expression.

#### Figure C
- **Hsp-27**: actin expression.

#### Figure D
- **NM23**: actin expression.

#### Figure E
- **DJ-1**: actin expression.

#### Figure F
- **PRDX2**: actin expression.

#### Figure G
- **TrpRS**: actin expression.
Fig. 6. Mémin et al.
Fig. 7. Mémin et al.

**eIF5A regulon**

- Hypusine-containing eIF5A
  - Translation of Group 1 mRNAs
  - Turnover of Group 2 mRNAs
  - Group 1 proteins
  - Group 2 proteins

- Cell proliferation, survival, tumorigenesis, anti-apoptosis
Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation

Elisabeth Memin, Mainul Hoque, Mohit R. Jain, et al.

Cancer Res  Published OnlineFirst November 12, 2013.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-0474

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/11/12/0008-5472.CAN-13-0474.DC1

Author Manuscript Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.